Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of the intranasal testosterone technology “in all applicable fields.”
Formerly known as Trimel, Acerus previously developed Natesto testosterone nasal gel, which was acquired by Aytu BioScience in 2016. In December 2018, the company announced Phase 1 results for an intranasal cannabis oil formulation.
Acerus President and CEO Ed Gudaitis said, “We are pleased to have partnered with UT Austin and Professor Josephs for the development of this technology. We expect that this new technology will allow us to develop therapeutic options that will complement our existing nasal technology. Acerus’ expertise in the formulation and development of nasally delivered active pharmaceutical ingredients, and more particularly testosterone, should enable Acerus to make this new technology a success.”
Read the Acerus press release.
